Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to $6.4 million.

  • Serina Therapeutics' Operating Expenses rose 2001.5% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 6288.59%. This contributed to the annual value of $17.1 million for FY2024, which is 17227.0% up from last year.
  • Serina Therapeutics' Operating Expenses amounted to $6.4 million in Q3 2025, which was up 2001.5% from $5.7 million recorded in Q2 2025.
  • In the past 5 years, Serina Therapeutics' Operating Expenses ranged from a high of $6.4 million in Q3 2025 and a low of $952000.0 during Q2 2023
  • Over the past 5 years, Serina Therapeutics' median Operating Expenses value was $2.2 million (recorded in 2021), while the average stood at $3.0 million.
  • As far as peak fluctuations go, Serina Therapeutics' Operating Expenses crashed by 5175.1% in 2023, and later skyrocketed by 31144.96% in 2024.
  • Serina Therapeutics' Operating Expenses (Quarter) stood at $1.9 million in 2021, then dropped by 5.49% to $1.8 million in 2022, then soared by 59.08% to $2.8 million in 2023, then surged by 94.48% to $5.5 million in 2024, then rose by 15.48% to $6.4 million in 2025.
  • Its Operating Expenses was $6.4 million in Q3 2025, compared to $5.7 million in Q2 2025 and $5.9 million in Q1 2025.